title: Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma.
abstract: Whereas normally expressed at sites of cell-to-cell contact in adult epithelial tissues, recent studies have shown that the receptor tyrosine kinase EphA2 is overexpressed in numerous epithelial-type carcinomas, with the greatest level of EphA2 expression observed in metastatic lesions. In the current study, we have assessed EphA2 expression in archived renal cell carcinoma (RCC) tissues as it relates to patient disease course. Using specific anti-EphA2 monoclonal antibody 208 and immunohistochemistry, we evaluated EphA2 protein expression levels in RCC specimens surgically resected from 34 patients (including 30 conventional clear-cell RCC, 3 papillary, and 1 chromophobic RCC cases) resulting in clinical cures. Regardless of histopathologic subtype, RCC lesions expressing higher levels of EphA2 tended to be of a higher grade (P < 0.05) and larger (P = 0.093), more-highly-vascularized tumors (P = 0.005). Perhaps most notable, the degree of EphA2 overexpression (versus normal matched autologous kidney tissue) seemed predictive of short-term (<1 year) versus longer-term (> or =1 year) disease-free interval (P < 0.001) and of overall survival (P < 0.001) among the RCC patients evaluated. These data suggest that EphA2 expression level may serve as a useful prognostic tool in the clinical management of patients who have been successfully treated with surgery, but who are at greater risk for accelerated disease recurrence and who have a poorer prognosis.
authors.affiliation: Department of Immunology and Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213-1863, USA.
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Herrem
authors.forename: Tomohide
authors.initials: T
authors.lastname: Tatsumi
authors.forename: Kathleen S
authors.initials: KS
authors.lastname: Olson
authors.forename: Keisuke
authors.initials: K
authors.lastname: Shirai
authors.forename: James H
authors.initials: JH
authors.lastname: Finke
authors.forename: Ronald M
authors.initials: RM
authors.lastname: Bukowski
authors.forename: Ming
authors.initials: M
authors.lastname: Zhou
authors.forename: Amy L
authors.initials: AL
authors.lastname: Richmond
authors.forename: Ithaar
authors.initials: I
authors.lastname: Derweesh
authors.forename: Michael S
authors.initials: MS
authors.lastname: Kinch
authors.forename: Walter J
authors.initials: WJ
authors.lastname: Storkus
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000737:chemistry; D002292:Carcinoma, Renal Cell / Q000175:diagnosis* / Q000378:metabolism* / Q000401:mortality / Q000601:surgery; D018572:Disease-Free Survival; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D007668:Kidney / Q000378:metabolism; D007680:Kidney Neoplasms / Q000175:diagnosis* / Q000378:metabolism* / Q000401:mortality / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic; D020411:Oligonucleotide Array Sequence Analysis; D011379:Prognosis; D036104:Receptor, EphA2 / Q000096:biosynthesis*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D036104:Receptor, EphA2